Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). I. Tolerability, adhesion and efficacy

Rozenbaum, H; Birkhäuser, Martin; Nooyer, Coenraad De; Lambotte, R; Pornel, Bruno; Schneider, H. P. G.; Studd, John

doi:10.1016/s0378-5122(96)01068-7

Cited by 34 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results are in accordance with those of the literature, and among the higher levels of efficacy [5,[24][25][26][27][28].…”

Section: Discussionsupporting

confidence: 91%

“…Women (421) The estradiol patches were administered continuously during six 28-day cycles; the opposing sequential (days [15][16][17][18][19][20][21][22][23][24][25][26][27][28] progestin in non-hysterectomized women was oral Milligynon (1.2 mg od). The main reason that women are prescribed combined rather than estrogen-only HRT is because of the increased risk of endometrial cancer associated with use of estrogen alone.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system

Raynaud

Lévrier

Calaf

et al. 2005

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…The results are in accordance with those of the literature, and among the higher levels of efficacy [5,[24][25][26][27][28].…”

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system

Raynaud

Lévrier

Calaf

et al. 2005

The Journal of Steroid Biochemistry and Molecular Biology

View full text Add to dashboard Cite

“…Estradiol was formulated as a TSS using a common cosmetic ingredient, octisalate, as a penetration enhancer [73]. The transdermal estradiol spray-on system is a clear solution that is sprayed on skin and dries within a minute resulting in no skin irritation [74][75][76].…”

Section: Areas Of Tss Application 41 Estradiol Spray-on Systemmentioning

confidence: 99%

Spray-on transdermal drug delivery systems

Ibrahim

2014

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

TSS is easily applied, delivering flexible drug dosage and associated with lower incidence of skin irritation. TSS provides a fast-drying product where the volatile solvent enables uniform drug distribution with minimal vehicle deposition on skin. TSS ensures precise dose administration that is aesthetically appealing and eliminates concerns of residual drug associated with transdermal patches. Furthermore, it provides a better alternative to traditional transdermal products due to ease of product development and manufacturing.

show abstract

“…Under "normal" conditions, complete detachment rates for hormone replacement therapy patches have been reported to range from 6% to 13%. 6,7 A contraceptive patch (Ortho Evra™/Evra™), which delivers 150 µg/day of the progestin norelgestromin (NGMN) and 20 µg/day of the estrogen ethinyl estradiol (EE) to systemic circulation, 8 has been developed. 9 The 20 cm 2 matrix patch is thin and consists of three layers: an outer protective layer; a medicated, adhesive middle layer; and a clear release liner that is removed prior to patch application.…”

mentioning

confidence: 99%

Pharmacokinetics of Norelgestromin and Ethinyl Estradiol Delivered by a Contraceptive Patch (Ortho Evra™/Evra™) under Conditions of Heat, Humidity, and Exercise

Abrams

Skee

Natarajan

et al. 2001

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The objectives of this randomized, open‐label, three‐period, incomplete block design study were to evaluate the pharmacokinetics of norelgestromin (NGMN) and ethinyl estradiol (EE) delivered by the contraceptive patch, Ortho EvraTM/EvraTM, and to evaluate patch adhesion under conditions of heat, humidity, and exercise. During each treatment period, 30 healthy women wore Ortho EvraTM on the abdomen for 7 days under one of six conditions (normal activity, sauna, whirlpool, treadmill, cool water immersion, ora combination of activities). Blood samples were collected before and several times to 240 hours after patch application. Mean serum concentrations of NGMN and EE generally remained within the reference ranges, 0.6 to 1.2 ng/ml and 25 to 75 pg/ml, respectively, duringthe 7‐day wear period for all activities. Only 1 (1.1%) of 87 patches completely detached spontaneously. Peel force measurements were comparable for all activities. Ortho EvraTM was well tolerated. In conclusion, Ortho EvraTM delivers efficacious concentrations of NGMN and EE and maintains adhesive reliability through 7 days of wear even under conditions of heat, humidity, and exercise.

show abstract

Comparison of two estradiol transdermal systems (Oesclim® 50 and Estraderm TTS® 50). I. Tolerability, adhesion and efficacy

Cited by 34 publications

References 18 publications

Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system

Comparison of the efficacy and tolerability of a new once-a-week matricial estradiol transdermal system (Estrapatch® 40 and Estrapatch® 60) with a twice week system

Spray-on transdermal drug delivery systems

Pharmacokinetics of Norelgestromin and Ethinyl Estradiol Delivered by a Contraceptive Patch (Ortho Evra™/Evra™) under Conditions of Heat, Humidity, and Exercise

Contact Info

Product

Resources

About